Since the PD‐1 inhibitor monotherapy is currently the standard treatment for the ESCC patients, the present study further analyzed the clinical efficacy of second‐line combination immunotherapy in immunotherapy‐naive ESCC patients. The gene discussed is PDCD1; the disease is esophageal squamous cell carcinoma.